FREE DOWNLOAD: Lay Summary Whitepaper

This complimentary lay summary whitepaper will explain:
- the ins and outs of lay summary writing,
- the importance of starting a pilot program,
- a checklist for lay reviewers, and
- strategic advice for becoming more transparent.
Click on the image for the full whitepaper.
This whitepaper was authored by Manager of Disclosures Services Kasim McLain, Senior Transparency Lead and Medical Writer Jennifer Pilgrim, and Associate Manager of Corporate Quality Jessica Alamdari.
Suggested For You

perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market

perspectives
January 30th, 2025
Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives
January 21st, 2025
REMS Modifications and Revisions: A Retrospective from the Past 12 Months

perspectives
January 9th, 2025
How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives
January 2nd, 2025
Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives
December 17th, 2024
Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives
December 11th, 2024
Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs

perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

perspectives
November 6th, 2024
How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives
October 29th, 2024
Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies